Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

Treatment options and patient perspectives in the management of fibromyalgia: future trends

Authors Kim Lawson

Published 5 December 2008 Volume 2008:4(6) Pages 1059—1071


Review by Single-blind

Peer reviewer comments 4

Kim Lawson

Biomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, UK

Abstract: Fibromyalgia (FM) is a common, complex, and difficult to treat chronic widespread pain disorder, which usually requires a multidisciplinary approach using both pharmacological and non-pharmacological (education and exercise) interventions. It is a condition of heightened generalized sensitization to sensory input presenting as a complex of symptoms including pain, sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the interrelationship of primary symptoms and the array of postulated triggers associated with FM. Many of the molecular targets of current and emerging drugs used to treat FM have been focused to the management of discrete symptoms rather than the condition. Recently, drugs (eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identified that demonstrate a multidimensional efficacy in this condition. Although the complexity of FM suggests that monotherapy, non-pharmacological or pharmacological, will not adequately address the condition, the outcomes from recent clinical trials are providing important clues for treatment guidelines, improved diagnosis, and condition-focused therapies.

Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological treatments

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer

Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S

OncoTargets and Therapy 2012, 5:199-211

Published Date: 24 September 2012

Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes

Opanasopit P, Paecharoenchai O, Rojanarata T, Ngawhirunpat T, Ruktanonchai U

International Journal of Nanomedicine 2011, 6:975-983

Published Date: 10 May 2011

Treatment of adult ADHD: Is current knowledge useful to clinicians?

Terje Torgersen, Bjørn Gjervan, Kirsten Rasmussen

Neuropsychiatric Disease and Treatment 2008, 4:177-186

Published Date: 8 February 2008

Effects of psycho-educational training and stimulant medication on visual perceptual skills in children with attention deficit hyperactivity disorder

Antigone S Papavasiliou, Irene Nikaina, Ioanna Rizou, Stratos Alexandrou

Neuropsychiatric Disease and Treatment 2007, 3:949-954

Published Date: 15 January 2008

Acamprosate: a new tool in the battle against alcohol dependence

Tara M Wright, Hugh Myrick

Neuropsychiatric Disease and Treatment 2006, 2:445-453

Published Date: 15 December 2006